CEO Executive AssistantRunning an early-stage biotech startup is a fundamentally different leadership challenge than running a software company of comparable size. A pre-IND biotech CEO manages a company where the primary asset is scientific data, the primary risk is clinical and regulatory, the primary investor base has deep technical expectations, and the timeline to revenue is measured in years rather than months. The time management demands that follow from these conditions are distinct, and the frameworks that work for SaaS or consumer startups do not map cleanly.
Biotech startup CEO time management from pre-IND through Phase 1 requires a system that balances scientific credibility, regulatory diligence, investor relations, and team building simultaneously, without the operational infrastructure of a large pharma company.
The Biotech CEO Role: Scientific Leader or General Manager?
The first time management question a biotech CEO faces is definitional: to what degree is the CEO’s value rooted in scientific credibility versus general management?
For founder-CEOs with scientific backgrounds (PhDs, MDs, or MD-PhDs), the temptation is to remain deeply embedded in the scientific work. This is appropriate in some cases and counterproductive in others. A CEO who is also the company’s leading scientific mind may genuinely need to stay close to the data. But a CEO who retreats into the science because it is more comfortable than fundraising, regulatory strategy, or team management is misallocating their most critical resource: leadership bandwidth.
For professional CEOs brought in to lead a scientist-founded biotech, the dynamic is reversed. The scientific credibility challenge is real: investors, potential partners, and the board will evaluate whether the CEO understands the science well enough to make informed strategic decisions and represent the company in technical discussions. This requires a consistent investment in scientific literacy, even if the CEO is not generating the data directly.
In either case, the time management principle is the same: the CEO should be the person best positioned to synthesize scientific progress with strategic and operational needs, not the person doing the most science or the person who delegates all science to others.
Scientific Advisory Board Time Investment
The scientific advisory board (SAB) is a critical asset for an early-stage biotech that is not typically used effectively as a time management tool. SAB members provide scientific validation that the CEO cannot supply alone: they signal to investors that the science is credible, they provide independent critique of the research approach, and they connect the company to academic and clinical networks that accelerate partnership and licensing discussions.
Biotech startup CEO time investment in the SAB should be front-loaded during company formation and then systematic thereafter. During the first twelve months, the CEO should invest significant time in SAB recruitment: identifying the right combination of domain expertise, clinical network, and academic credibility; conducting personal outreach and recruitment conversations; and structuring the SAB engagement terms (equity, compensation, meeting frequency, scope of involvement).
A strong SAB for a pre-IND biotech typically includes three to six members: at least one scientist with deep expertise in the relevant mechanism or target class; at least one clinician with experience in the relevant indication; and optionally one or two members with regulatory, formulation, or manufacturing expertise depending on the program’s specific risks.
After formation, the CEO’s time investment in SAB management is approximately four to six hours per SAB meeting, plus bilateral check-ins between meetings. A quarterly SAB meeting cadence is standard for pre-IND companies. For programs entering IND-enabling studies, some companies shift to bi-monthly SAB engagement because the scientific questions are moving faster.
The CEO should attend every SAB meeting, not delegate attendance to the CSO. The CEO’s presence signals that SAB input shapes strategy, not just science. The CEO should also maintain bilateral relationships with each SAB member outside of formal meetings: a thirty-minute call every quarter to discuss the program’s progress, share relevant publications, and understand what the SAB member is seeing in the broader field.
IND Preparation Oversight
The IND (Investigational New Drug) application is the first major regulatory milestone for a small molecule or biologic program. Preparing a strong IND requires coordinating across pharmacology, toxicology, manufacturing/CMC, and clinical operations, often with external CROs and CDMOs. For a small team without a seasoned regulatory affairs leader, this coordination is complex and timeline-critical.
The CEO’s role in IND preparation is not to manage the regulatory process directly; it is to ensure that the regulatory strategy is sound and that the execution infrastructure (internal team, CRO selection, CDMO partnerships) is properly resourced and governed.
Specific CEO responsibilities in IND preparation oversight: Participating in the Type B pre-IND meeting with FDA (if pursued), because this meeting sets the development path and the CEO’s presence signals executive commitment. Approving the CRO and CDMO selection for key IND-enabling studies, which often represents the company’s largest near-term financial commitments. Reviewing the IND timeline against the financing plan: a common early-stage biotech mistake is an IND timeline that does not match the runway, requiring a fundraise in the middle of critical IND-enabling work. Ensuring the regulatory strategy is peer-reviewed by an experienced regulatory consultant if the internal team does not have direct IND experience.
Time allocation for IND preparation oversight: approximately twenty to thirty hours spread across the six to twelve months of IND-enabling work, concentrated in the pre-IND meeting preparation, CRO/CDMO selection, and timeline-to-financing alignment review.
Time management for startups in regulated industries covers the general principles for governance of regulatory processes that also apply in the biotech context.
Biotech Investor Relations Specifics
Biotech investor relations differ from typical venture investor relations in several important respects, each with time management implications.
Technical diligence intensity. Biotech investors conduct substantially deeper technical diligence than software investors. Data room preparation for a biotech financing round typically requires two to four weeks of effort from the scientific and management team, not the one-week sprint that a software Series A might require. The CEO should plan the fundraising calendar to account for this: start data room preparation eight to ten weeks before the investor process begins, not six weeks.
Staged funding structures. Biotech financing is frequently structured around clinical or regulatory milestones (e.g., financing tranches tied to IND filing, Phase 1 initiation, or interim clinical data readouts). This means the CEO is often managing ongoing investor relations against a milestone calendar, not just a general growth narrative. Investor updates should be structured around milestone progress, not just financial metrics.
Scientific presentation requirements. Biotech investor meetings typically include a scientific presentation by the CEO or CSO. The CEO’s preparation for investor meetings must include deep familiarity with the current data package: the in vitro and in vivo results, the mechanistic rationale, the competitive landscape in the target indication, and the regulatory path. This preparation cannot be delegated; the CEO must be able to answer detailed scientific questions credibly.
Syndicate management. Early-stage biotech financings often involve a lead investor plus several co-investors (biotech-focused VCs, crossover funds, family offices with biotech interest, occasionally strategic corporate investors). Managing the syndicate requires more active relationship maintenance than a single-investor round. The CEO should plan for bilateral quarterly touchpoints with each investor in the syndicate, not just the lead.
Time investment in biotech investor relations for a pre-IND company: approximately fifteen to twenty percent of the CEO’s working time in a non-fundraising quarter; forty to fifty percent during an active fundraising process.
Team Building Without Large Pharma Infrastructure
Early-stage biotech startups typically operate with very small internal teams (five to fifteen people) and accomplish most of their preclinical and IND-enabling work through a network of CROs, CDMOs, and academic collaborators. This structure creates specific time management challenges for the CEO.
Hiring decisions have outsized impact. In a fifteen-person biotech, every key hire is a significant fraction of total capacity. The CEO must be directly involved in every VP and director-level hire, and should invest real time in the hiring process: reviewing candidate sourcing strategy, conducting structured interviews, checking references personally for senior candidates, and making the final offer calls. Do not delegate the hiring of your CSO, CMO, VP of Regulatory, or VP of Manufacturing to a recruiter alone.
CRO and CDMO management is a hidden leadership demand. Managing external research organizations effectively requires relationship investment that many biotech CEOs underestimate. A CRO partner who has the CEO’s attention delivers differently than one who interacts only with a project manager. Quarterly business reviews with key CRO and CDMO partners, attended by the CEO, signal that these relationships are strategic rather than transactional.
Culture in a small, technically specialized team. Building a culture of scientific rigor combined with urgency is harder in a small biotech than it sounds. The CEO sets this culture by direct example: how they engage with data (with curiosity and skepticism, not confirmation bias), how they respond to negative preclinical results (with analytical rigor, not denial), and how they treat the scientists and clinicians on the team.
Managing the Scientific-Commercial Interface
One of the most time-consuming aspects of early biotech CEO leadership is managing the interface between scientific development and commercial strategy. Many early-stage biotechs are built around a single program or a narrow platform, and the commercial strategy (indication selection, patient population, development path, potential partnership or licensing approach) must be decided while the science is still unfolding.
The CEO’s role is to ensure that commercial strategy does not run ahead of or behind the science. A common failure mode: commercial teams or investors push for the largest possible indication because it maximizes valuation, while the science supports a narrower initial target. The CEO must navigate this tension with both analytical rigor and stakeholder management skill.
Indication selection decisions, partnership strategy, and licensing discussions all require CEO involvement because they involve trade-offs between scientific risk, commercial opportunity, and financial runway. These decisions should be made in structured strategy sessions, not improvised in investor meetings or board conversations.
Managing scientific and operational complexity in early-stage companies provides adjacent frameworks for CEOs leading companies where the technical complexity shapes the entire operating model.
Biotech Startup CEO Time Allocation Model
A suggested quarterly time allocation for a pre-IND biotech CEO with a single lead program:
Scientific and technical oversight: 20-25% (SAB management, IND-enabling study oversight, CRO/CDMO governance)
Investor relations and fundraising: 20-30% (depending on whether an active financing is underway)
Team building and management: 15-20% (hiring, one-on-ones with direct reports, culture and performance management)
Regulatory strategy and partnership development: 10-15% (pre-IND meeting preparation, potential partnership outreach, IP strategy)
External representation: 10-15% (conferences, key opinion leader relationship management, scientific publication strategy)
Operational management: 5-10% (budget oversight, board governance, administrative leadership)
This allocation will shift significantly as the company moves into Phase 1: clinical operations management increases substantially, investor relations often intensifies as interim data approaches, and the CEO’s scientific oversight role may narrow as the clinical team takes over from the preclinical team.
Biotech Startup CEO Time Management: Operating Principles
The most important time management principle for a biotech CEO at this stage is to resist the constant pull toward operational detail at the expense of strategic leadership. The operational detail is genuinely important in biotech; scientific execution errors at the IND stage can set the program back by years. But the CEO’s value is not in personally managing the details; it is in making the strategic decisions, securing the financing, building the team, and representing the company in the external forums where credibility determines whether the company survives long enough to generate data.
For frameworks on how leading biotech investors evaluate early-stage program development and team building, First Round Capital’s research on deep-tech and bio company building provides useful perspective: First Round Review on hard tech company building.
Scientific credibility takes years to build and hours to lose. Protect both the science and the CEO’s strategic bandwidth, and treat the balance between them as the primary time management challenge of the role.
Related Reading
For further context, explore Time Management for AI Startup CEOs and Time Management for Climate Tech Startup CEOs.